Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

Christopher W Ryan,Catherine M Tangen,Elisabeth I Heath,Mark N Stein,Maxwell V Meng,Ajjai S Alva,Sumanta K Pal,Igor Puzanov,Joseph I Clark,Toni K Choueiri,Neeraj Agarwal,Robert G Uzzo,Naomi B Haas,Timothy W Synold,Melissa Plets,Ulka N Vaishampayan,Brian M Shuch,Ian M Thompson,Primo N Lara

Lancet (London, England)（2023）

引用 3|浏览33

暂无评分

摘要

US National Institutes of Health, National Cancer Institute, National Clinical Trials Network, Novartis Pharmaceuticals Corporation, and The Hope Foundation.

查看译文

关键词

adjuvant everolimus,renal cell carcinoma,double-blind,placebo-controlled

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要